[Early anocutaneous metastases of rectal cancer after transanal resection with stapled anastomosis].

PubWeight™: 0.75‹?›

🔗 View Article (PMID 15671946)

Published in Gastroenterol Clin Biol on December 01, 2004

Authors

Céline Delluc, Jean-Marc Gornet, Pierre Cattan, Maria Nachury, Matthieu Allez, Philippe Bertheau, Marc Lémann

Articles by these authors

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68

Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology (2013) 3.45

Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet (2010) 3.22

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology (2011) 3.08

Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 2.95

Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology (2013) 2.78

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74

Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. Clin Gastroenterol Hepatol (2008) 2.50

CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest (2007) 2.44

Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology (2008) 2.39

Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol (2009) 2.36

Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27

Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20

The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology (2004) 2.02

Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology (2006) 2.01

Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut (2010) 1.87

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80

Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol (2009) 1.78

Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis (2010) 1.78

Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology (2010) 1.73

A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol (2008) 1.70

A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis (2006) 1.70

Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci U S A (2002) 1.63

Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol (2002) 1.49

Erythromycin improves the quality of EGD in patients with acute upper GI bleeding: a randomized controlled study. Gastrointest Endosc (2002) 1.49

Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas. Eur J Nucl Med Mol Imaging (2013) 1.48

CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology (2007) 1.47

Delineation of a CD1d-restricted antigen presentation pathway associated with human and mouse intestinal epithelial cells. Gastroenterology (2003) 1.45

Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol (2005) 1.43

Primary hyperparathyroidism from parathyroid microadenoma: specific features and implications for a surgical strategy in the era of minimally invasive parathyroidectomy. J Am Coll Surg (2010) 1.42

Crohn's disease over 20 years after diagnosis in a referral population. Gastroenterol Clin Biol (2004) 1.41

Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis (2012) 1.39

Dexmedetomidine for prevention of postoperative delirium in older adults undergoing oesophagectomy with total intravenous anaesthesia. Eur J Anaesthesiol (2022) 1.39

A comparative study of endothelial cell markers expressed in chronically inflamed human tissues: MECA-79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146. J Pathol (2005) 1.38

Patchy distribution of mucosal lesions in ileal Crohn's disease is not linked to differences in the dominant mucosa-associated bacteria: a study using fluorescence in situ hybridization and temporal temperature gradient gel electrophoresis. Inflamm Bowel Dis (2007) 1.37

Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res (2013) 1.36

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis (2010) 1.32

Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology (2011) 1.25

Th17/Treg ratio in human graft-versus-host disease. Blood (2010) 1.19

Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res (2013) 1.16

Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med (2010) 1.16

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol (2010) 1.15

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis (2009) 1.14

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat (2010) 1.13

Ketosis-prone type 2 diabetes mellitus and human herpesvirus 8 infection in sub-saharan africans. JAMA (2008) 1.13

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene (2002) 1.10

Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev (2013) 1.08

Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma. Am J Physiol Gastrointest Liver Physiol (2007) 1.08

Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol (2004) 1.06

Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer (2012) 1.04

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut (2012) 1.03

Foreign bodies and caustic lesions. Best Pract Res Clin Gastroenterol (2013) 1.03

Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis (2005) 1.03

Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum (2005) 1.03

Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.02

Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis (2009) 1.02

Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis (2011) 1.01

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer (2009) 1.01

Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease. Gastroenterology (2011) 1.00

TP53 status and response to treatment in breast cancers. J Biomed Biotechnol (2011) 0.99

Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis (2013) 0.99

Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. Blood (2008) 0.98

Surgery for caustic injuries of the upper gastrointestinal tract. Ann Surg (2012) 0.97

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist (2010) 0.97

Late morbidity after colon interposition for corrosive esophageal injury: risk factors, management, and outcome. A 20-years experience. Ann Surg (2010) 0.96

Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer (2010) 0.96

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer (2013) 0.95

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. Inflamm Bowel Dis (2014) 0.95

Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol (2010) 0.93

Genotype/phenotype analyses for 53 Crohn's disease associated genetic polymorphisms. PLoS One (2012) 0.93

Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis (2007) 0.93

Colopharyngoplasty for the treatment of severe pharyngoesophageal caustic injuries: an audit of 58 patients. Ann Surg (2007) 0.93

Paracellular versus transcellular intestinal permeability to gliadin peptides in active celiac disease. Am J Pathol (2011) 0.93

Clinical severity scores in gastrointestinal graft-versus-host disease. Transplantation (2014) 0.92

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res (2013) 0.92

High frequency of fatal haemophagocytic lymphohistiocytosis syndrome in enteropathy-associated T cell lymphoma. Dig Liver Dis (2011) 0.91

Crohn's disease recurrence after total proctocolectomy with definitive ileostomy. Dig Liver Dis (2011) 0.91